Jane Abbott Rider
Adult Health · Peru, INNPI 1508800608
Payments from drug & device makers
Across 88 payments — averaging $27.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$417
- Johnson & Johnson$366
- Otsuka America Pharmaceutical, Inc.$283
- Teva Pharmaceuticals USA, Inc.$276
- AbbVie$236
- Neurocrine Biosciences, Inc.$233
- plus $571 from 7 others
What the payments were for
- Food & beverage$2,22693%
- Education$1557%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 14 | $417 |
| Johnson & Johnson | 20 | $366 |
| Otsuka America Pharmaceutical, Inc. | 10 | $283 |
| Teva Pharmaceuticals USA, Inc. | 11 | $276 |
| AbbVie | 13 | $236 |
| Neurocrine Biosciences, Inc. | 3 | $233 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $224 |
| Alkermes, Inc. | 5 | $135 |
| Axsome Therapeutics, Inc. | 1 | $118 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Corium, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$345
- ABILIFY MAINTENA$246
- ABILIFY ASIMTUFII$246
- INGREZZA$228
- VRAYLAR$125
- INVEGA SUSTENNA$125
- CAPLYTA$124
- Auvelity$118
How this compares
$2,382 in reported general payments places this provider in the 80th percentile of 391 adult health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 108 | $365,842 |
| IngrezzaValbenazine Tosylate | 43 | $353,905 |
| Austedo XrDeutetrabenazine | 20 | $218,358 |
| VraylarCariprazine Hcl | 86 | $119,671 |
| Abilify MaintenaAripiprazole | 25 | $69,331 |
| CaplytaLumateperone Tosylate | 31 | $52,462 |
| Paliperidone ErPaliperidone | 110 | $32,667 |
| Aripiprazole | 207 | $27,552 |
| Lurasidone Hcl | 93 | $17,321 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 106 | $10,032 |
| Risperdal ConstaRisperidone Microspheres | 12 | $8,425 |
| Clozapine | 37 | $7,132 |
| TrintellixVortioxetine Hydrobromide | 14 | $7,098 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 66 | $5,839 |
| Chlorpromazine Hcl | 21 | $5,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $366 | $374,267120 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $233 | $353,90543 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $276 | $218,35820 claims |
| AbbVieVraylar | $236 | $119,67186 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $283 | $69,33125 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $224 | $52,46231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 adult health providers in Indiana.
Other adult health in Peru
- Joyce PittmanIndianapolis$177K
- Jennifer BerryIndianapolis$50K
- Tajuana DavisZionsville$31K
- Patricia Damron-RobinsonMerrillville$20K
- Terry RidgeCarmel$20K
- Kristine StarcevichMerrillville$19K
- Jolyn Holliday VezaGreenfield$17K
- Anna MatulewiczMishawaka$14K
- Ludmila Pichugena-EmersonMiddlebury$14K
- Vincent SmithMerrillville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.